Spring Bank Announces Positive Results from the Recently Completed Phase 2 Chronic Hepatitis B ACHIEVE Trial and Additional Inarigivir Studies

NEXT STORY
TRACON Pharmaceuticals Announces Termination of Phase 3 TAPPAS Trial Based on the Recommendation of the Independent Data Monitoring Committee
PREV STORY
Press release: Curetis’ Subsidiary Ares Genetics Introduces NGS Services for Pharma and Public Health Sector at Upcoming ECCMID 2019
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Women’s Health Diagnostics Market Report to 2031: Visiongain Research Inc.

author_avatar
NASDAQ Market News

Press Release Oncology Venture is issuing 2,255,639 shares under its convertible note agreement with Negma Group LTD and Park Partners GB

author_avatar
NASDAQ Market News

Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals

Apricus Expects to Receive Approximately $12.7 Million from Ferring Apricus to Focus on Vitaros ...

author_avatar
NASDAQ Market News